Joseph H. Gardner
Founder at Aerpio Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Anupam Dalal | M | 52 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 9 years |
| John Butler | M | 59 | 11 years | |
| Caley Castelein | M | 53 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
| Cheryl Cohen | F | 58 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 6 years |
| Mitchell Brigell | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
| Stephen Pakola | M | 55 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 9 years |
| Nicole Hadas | F | 51 | 11 years | |
| Michel Dahan | M | 45 | 11 years | |
| Kevin G. Peters | M | 67 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 11 years |
| Dietmar Vestweber | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Chris Kontos | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert A. Shalwitz | M | 69 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
| Muneer Satter | M | 63 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
| Steven Prelack | M | 66 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 4 years |
| Michael Rogers | M | 64 | 2 years | |
| Regina Marek | F | 55 | 3 years | |
| John M. Rice | M | 74 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 11 years |
| Chau Khuong | M | 48 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 6 years |
| Duane Nash | M | 53 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 6 years |
| Pravin Dugel | M | 60 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 4 years |
| Rick Rees | M | - |
Tulane University (Louisiana)
| 5 years |
| Jack Nielsen | M | 60 | 2 years | |
| Tevfik Özakat | M | 68 |
University of Wisconsin
| 6 years |
| Kim Lennart Dueholm | M | 61 | 1 years | |
| Khalid Hamad Al-Yahya | M | 65 |
University of Wisconsin
| 5 years |
| Dhaval Desai | M | - | 4 years | |
| Jeff Schmidt | M | - |
Tulane University (Louisiana)
| 6 years |
| Jim Tatera | M | - |
University of Wisconsin
| 2 years |
| Grant Berlin | M | - |
University of Wisconsin
| 8 years |
| Mohammad Khalid Osama Asfour | M | 59 |
University of Wisconsin
| 6 years |
| Josh Fairbank | M | - | - | |
| Brian Clement Israelsen | M | - |
Utah State University
| 5 years |
| Nasser Farid Akram | M | - |
University of Wisconsin
| 6 years |
| Lynette M. Zigman | F | - |
University of Wisconsin
| 4 years |
| Jeffrey A. Kaczmarski | M | - |
University of Wisconsin
| 7 years |
| Henry M. McMillan | M | - |
University of Wisconsin
| 3 years |
| Steven T. Berman | M | 61 |
University of Wisconsin
| 7 years |
| Jun Ni | M | 61 |
University of Wisconsin
| 4 years |
| Yu Neng Lim | M | 61 |
University of Wisconsin
| 5 years |
| Boon San Gan | M | 62 |
University of Wisconsin
| 5 years |
| Christopher John Scheuer | M | - |
University of Wisconsin
| 14 years |
| Mark Keeling | M | - |
University of Wisconsin
| 6 years |
| Stephen Hoffman | M | 70 | 2 years | |
| Adrienne Graves | M | 69 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 5 years |
| John Harold Underwood | M | - |
University of Wisconsin
| 5 years |
| Stephen Petersen | M | 68 |
University of Wisconsin
| 5 years |
| Kenneth Hanson Crawford | M | - |
University of Wisconsin
| 5 years |
| Dan Becker | M | - |
University of Wisconsin
| 6 years |
| Robert Lazzara | M | - |
Tulane University (Louisiana)
| 5 years |
| Mike E. Pape | M | - | - | |
| Gary Nussbaum | M | 60 |
University of Wisconsin
| 6 years |
| Phill Gross | M | - |
University of Wisconsin
| 5 years |
| Jay Robert Sekelsky | M | 65 |
University of Wisconsin
| 6 years |
| Eric Fitzgerald Richter | M | - |
University of Wisconsin
| 6 years |
| Mark Richard Mirsberger | M | - |
University of Wisconsin
| 6 years |
| John E. Carlson | M | - |
University of Wisconsin
| 5 years |
| Daniel Robert Chappie | M | - |
University of Wisconsin
| 4 years |
| Gregory H. Sachs | M | 59 |
University of Wisconsin
| 7 years |
| Scott P. Spector | M | - |
Tulane University (Louisiana)
| 7 years |
| Stuart Michael Rossmiller | M | - |
University of Wisconsin
| 9 years |
| Robert Piepenburg | M | - |
University of Wisconsin
| 6 years |
| Catherine Leslie Witeck | F | - |
University of Wisconsin
| 6 years |
| Brian K. Yeazel | M | - |
University of Wisconsin
| 6 years |
| Jill Marie Grueninger | F | - |
University of Wisconsin
| 6 years |
| Joseph Toomy | M | 75 |
Tulane University (Louisiana)
| 6 years |
| Michael B. Zemel | M | - |
University of Wisconsin
| 3 years |
| Karen R. Makowski | F | 67 |
University of Wisconsin
| 1 years |
| Cindy Kaiser | F | - |
University of Wisconsin
| 4 years |
| Jim Janikowski | M | - |
University of Wisconsin
| 4 years |
| Gregg E. Lawry | M | - |
University of Wisconsin
| 4 years |
| Narumol Wangsatorntanakun | F | 68 |
University of Wisconsin
| 3 years |
| Greg Hart | M | 58 |
University of Wisconsin
| 4 years |
| Tracy Bolger | F | - |
University of Wisconsin
| 4 years |
| Joel T. Leonard | M | - |
University of Wisconsin
| 4 years |
| Stephen H. Siegele | M | 64 |
University of Wisconsin
| 4 years |
| Gerald D. Schiefelbein | M | 65 |
University of Wisconsin
| 4 years |
| Diane L. Ford | F | 70 |
University of Wisconsin
| 2 years |
| Allan J. Klotsche | M | 59 |
University of Wisconsin
| 4 years |
| Kevin Gordon Grant | M | - |
University of Wisconsin
| 4 years |
| James Bedore | M | 64 |
University of Wisconsin
| 4 years |
| Dave Spano | M | 59 |
University of Wisconsin
| 4 years |
| Charles Merinoff | M | - |
University of Wisconsin
| 4 years |
| Mike G. Reinecke | M | - |
University of Wisconsin
| 4 years |
| Roy Shepard | M | - |
University of Wisconsin
| 2 years |
| Jordan Dolin | M | - |
University of Wisconsin
| 4 years |
| Jen Chiu Kuo | M | 58 |
University of Wisconsin
| 4 years |
| Thomas Jurgensen | M | 66 |
University of Wisconsin
| 4 years |
| Kent E. Willetts | M | - |
University of Wisconsin
| 4 years |
| Sakir Sömek | M | 61 |
University of Wisconsin
| 4 years |
| Jeffrey Lawrence Peskind | M | - |
University of Wisconsin
| 2 years |
| Gary King | M | - |
University of Wisconsin
| 4 years |
| Steven Jaeger | M | 59 |
University of Wisconsin
| 4 years |
| Paul Beduhn | M | - |
University of Wisconsin
| 4 years |
| John C. Wayne | M | 62 |
University of Wisconsin
| 4 years |
| Peter Elenius | M | - |
University of Wisconsin
| 4 years |
| Greg Pearson | M | 63 |
University of Wisconsin
| 4 years |
| Rick A. Eustice | M | - |
University of Wisconsin
| 4 years |
| Kerry S. Arent | F | - |
University of Wisconsin
| 4 years |
| Doug Dyer | M | - |
University of Wisconsin
| 4 years |
| Randall Sharpton | M | - |
University of Wisconsin
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph H. Gardner
- Personal Network
